A biomarker test to measure progression for Parkinson's Disease is available in the US before 2029
Salud y medicinaOne-Off2aManifold MarketsSin KYCDatos de resolución verificadosCalibración aceptablePronóstico comunitario actualSí 71.7%
Pronosticadores
6
Tipo de pregunta
binary
Metodología
Play-money forecasting platform
Tipo de fuente
Pronóstico
Datos de mercado
Actualizado hace 17 horas
Desactualizado25 abr 23, 16:13 UTC2 ene 29, 6:59 UTC
Tendencias
Reglas
There will be a test of a biomarker which meaningfully correlates with parkinson's progression for at least a signficant subset (>10% of those diagnosed clinically) of people with Parkinson's disease in the US before 2029
- examples: Patient has classic non-genetic PD from a clinical diagnosis based on symptoms (rigidity, etc.).
- There will be a test which they can take which shows the severity of the disease, and which when given repeatedly can be used to measure how much or less the disease has progressed
